Published in AIDS on February 14, 2003
CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro. Clin Immunol (2003) 1.48
Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission. J Virol (2005) 1.30
Relationship between HIV coreceptor tropism and disease progression in persons with untreated chronic HIV infection. J Acquir Immune Defic Syndr (2009) 1.24
CCR5Delta32 genotypes in a German HIV-1 seroconverter cohort and report of HIV-1 infection in a CCR5Delta32 homozygous individual. PLoS One (2008) 1.10
Chemokine receptor 5 △32 allele in patients with severe pandemic (H1N1) 2009. Emerg Infect Dis (2010) 1.03
Role of HIV Gp41 mediated fusion/hemifusion in bystander apoptosis. Cell Mol Life Sci (2008) 1.00
A comprehensive review on host genetic susceptibility to human papillomavirus infection and progression to cervical cancer. Indian J Hum Genet (2011) 0.92
Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic Approaches. Front Immunol (2013) 0.92
CCR2-V64I polymorphism is associated with increased risk of cervical cancer but not with HPV infection or pre-cancerous lesions in African women. BMC Cancer (2010) 0.87
HIV replication capacity is an independent predictor of disease progression in persons with untreated chronic HIV infection. J Acquir Immune Defic Syndr (2010) 0.83
Genetic variation and HIV-associated neurologic disease. Adv Virus Res (2013) 0.81
Interactions of HIV and drugs of abuse: the importance of glia, neural progenitors, and host genetic factors. Int Rev Neurobiol (2014) 0.81
CCR2 and CCR5 genes polymorphisms in women with cervical lesions from Pernambuco, Northeast Region of Brazil: a case-control study. Mem Inst Oswaldo Cruz (2016) 0.80
CCR2-64I polymorphism is associated with lower maternal HIV-1 viral load and reduced vertical HIV-1 transmission. J Acquir Immune Defic Syndr (2009) 0.79
TCR triggering transcriptionally downregulates CCR5 expression on rhesus macaque CD4(+) T-cells with no measurable effect on susceptibility to SIV infection. Virology (2010) 0.78
Risk of all-cause mortality in HIV infected patients is associated with clinical, immunologic predictors and the CCR5 Δ32 deletion. PLoS One (2011) 0.77
Distribution of CCR5-Delta32, CCR5 promoter 59029 A/G, CCR2-64I and SDF1-3'A genetic polymorphisms in HIV-1 infected and uninfected patients in the west region of Cameroon. BMC Res Notes (2013) 0.77
Risk of HIV Infection and Lethality Are Decreased in CCR5del32 Heterozygotes: Focus Nosocomial Infection Study and Meta-analysis. Acta Naturae (2012) 0.77
CCR2, CCR5, and CXCL12 variation and HIV/AIDS in Papua New Guinea. Infect Genet Evol (2015) 0.75
Effects of CCR5-delta32 and CCR2-641 alleles on HIV-1 disease progression: the protection varies with duration of infection, by Mulherin et al. AIDS (2003) 0.75
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 12.98
Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol (2011) 12.10
A high-density admixture map for disease gene discovery in african americans. Am J Hum Genet (2004) 10.87
Psychological sequelae of the September 11 terrorist attacks in New York City. N Engl J Med (2002) 10.07
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet (2008) 9.00
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet (2008) 8.37
HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (2004) 8.22
Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet (2002) 7.58
Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS (2006) 7.08
Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet (2007) 6.83
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog (2013) 6.14
Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer (2008) 6.13
Protection against persistence of hepatitis C. Lancet (2002) 5.94
Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS (2003) 5.85
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS (2010) 5.85
Canadian illicit opiate users' views on methadone and other opiate prescription treatment: an exploratory qualitative study. Subst Use Misuse (2002) 5.65
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature (2012) 5.49
When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med (2011) 5.35
Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med (2007) 5.22
The New York Cancer Project: rationale, organization, design, and baseline characteristics. J Urban Health (2004) 5.21
Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr (2008) 5.05
Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol (2007) 4.96
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity (2013) 4.82
APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol (2011) 4.80
Merkel cell carcinoma and HIV infection. Lancet (2002) 4.72
Medicine. The need for a global HIV vaccine enterprise. Science (2003) 4.70
Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst (2011) 4.69
Standardization of cytokine flow cytometry assays. BMC Immunol (2005) 4.55
Pathway analysis by adaptive combination of P-values. Genet Epidemiol (2009) 4.48
Cancer in dyskeratosis congenita. Blood (2009) 4.28
Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA (2006) 4.26
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med (2015) 4.26
Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990-98. Addiction (2003) 4.25
Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med (2008) 4.21
The epidemiology of post-traumatic stress disorder after disasters. Epidemiol Rev (2005) 4.09
Television images and psychological symptoms after the September 11 terrorist attacks. Psychiatry (2002) 4.07
LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell (2008) 4.02
HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc Natl Acad Sci U S A (2005) 4.02
Trends of probable post-traumatic stress disorder in New York City after the September 11 terrorist attacks. Am J Epidemiol (2003) 3.93
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature (2012) 3.83
HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis (2005) 3.77
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
The characterization of twenty sequenced human genomes. PLoS Genet (2010) 3.72
Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management? Neurology (2012) 3.63
HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis (2007) 3.56
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis (2005) 3.52
Risk behaviors by audio computer-assisted self-interviews among HIV-seropositive and HIV-seronegative injection drug users. AIDS Educ Prev (2002) 3.45
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med (2008) 3.42
The social epidemiology of substance use. Epidemiol Rev (2004) 3.41
A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS (2002) 3.41
The UCSC Cancer Genomics Browser: update 2011. Nucleic Acids Res (2010) 3.37
Challenges and facilitating factors in sustaining community-based participatory research partnerships: lessons learned from the Detroit, New York City and Seattle Urban Research Centers. J Urban Health (2006) 3.36
Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci U S A (2012) 3.33
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet (2002) 3.32
Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. Am J Public Health (2004) 3.32
Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. Am J Epidemiol (2003) 3.29
AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst (2007) 3.28
Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load. J Virol (2004) 3.28
Influence of HLA-C expression level on HIV control. Science (2013) 3.27
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med (2013) 3.24
A road map for efficient and reliable human genome epidemiology. Nat Genet (2006) 3.21
Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst (2006) 3.17
Social determinants and the health of drug users: socioeconomic status, homelessness, and incarceration. Public Health Rep (2002) 3.14
Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med (2012) 3.12
Evaluation of an intervention to increase screening colonoscopy in an urban public hospital setting. J Urban Health (2006) 3.10
Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol (2010) 3.09
Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis (2005) 3.06
Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol (2005) 3.04
HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet (2009) 3.03
Urban health: evidence, challenges, and directions. Annu Rev Public Health (2005) 3.02
Population-based HIV-1 incidence in France, 2003-08: a modelling analysis. Lancet Infect Dis (2010) 3.01
Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol (2013) 3.00
AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. Nat Med (2005) 2.97
What drives the US and Peruvian HIV epidemics in men who have sex with men (MSM)? PLoS One (2012) 2.97
Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis (2007) 2.90
Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood (2006) 2.90
Host determinants of HIV-1 control in African Americans. J Infect Dis (2010) 2.90
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis (2012) 2.89
Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell (2013) 2.88
Age-specific trends in incidence of noncardia gastric cancer in US adults. JAMA (2010) 2.78
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
Dominant TNF-α+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nat Med (2011) 2.77
Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst (2013) 2.76
HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol A Biol Sci Med Sci (2007) 2.75
Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol Rev (2006) 2.75